Corcept Therapeutics Incorporated (CORT) Reports 105-Month Response in One Cancer Patient
Corcept Therapeutics (CORT) reported a single patient with metastatic vulvar cancer responded to relacorilant plus nab-paclitaxel for over 105 months. The patient remains in treatment with stable disease, but the company cautioned this is an early case and may not reflect broader outcomes.
How this was made

The 30-second read
Why it matters
The unusually long response could attract investor attention and potential partnership interest, but clinical significance remains uncertain.
Market read
A rare, long‑term response in a heavily pretreated patient may boost speculative interest in CORT.
What to watch
Regulatory pathway and need for larger trials could delay commercial impact.
Background
Corcept Therapeutics (CORT) focuses on glucocorticoid‑receptor antagonists; relacorilant is its lead candidate.
Ticker impact
Corcept disclosed a 105‑month response in a single metastatic vulvar cancer patient to relacorilant plus nab‑paclitaxel.
potential upside as investors weigh the unprecedented response signal
The result is novel and positive, yet limited to one patient, so market reaction may be modest.
Market effects
may raise interest in glucocorticoid‑receptor antagonists and niche oncology pipelines
limited to US biotech investors
minimal beyond specialty oncology niche
Counterpoint
Skeptics may view the single‑patient data as anecdotal and not price‑moving.
Key entities
- companyCorcept Therapeutics Incorporated
Biopharma developing relacorilant.


